Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average “Hold” Recommendation From Brokerages

0

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) received an average rating of “Hold” from the fourteen rating agencies that cover the stock, reports MarketBeat. Eight analysts rated the stock with a hold rating and two gave the company a buy rating. The average 1-year price target among brokerages that updated their coverage on the stock in the last year is $45.83.

A number of brokerages have recently released FMS reports. DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 report. Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a Wednesday, June 22 report . StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Thursday, Aug. 25 research note. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research note. Finally, Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and raised its price target for the stock from $30.30 to $33.70 in a Monday, June 27 research note.

Fresenius Medical Care AG & Co. KGaA share performance

A d Legacy search

Market Wizard Who Accurately Predicted 2022 Market Crash Has Shocking New Predictions

He predicted 2020’s crash a month before it happened… He predicted this year’s crash in January… And now he’s issuing a brand new warning – with a unique solution.

NYSE FMS shares opened at $16.81 on Monday. The company’s 50-day moving average price is $19.89 and its 200-day moving average price is $26.76. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. The company has a market capitalization of $9.85 billion, a PE ratio of 10.71, a PEG ratio of 0.84 and a beta of 1.03. Fresenius Medical Care AG & Co. KGaA has a 52-week minimum of $16.06 and a 52-week maximum of $36.97.

Institutional investors weigh in on Fresenius Medical Care AG & Co. KGaA

Institutional investors and hedge funds have recently increased or reduced their stake in the company. FDx Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA during Q1 for a value of approximately $315,000. Freestone Capital Holdings LLC purchased a new equity stake in Fresenius Medical Care AG & Co. KGaA during the first quarter, valued at approximately $390,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 18.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,706 shares of the company valued at $158,000 after buying 730 additional shares in the last quarter. Cacti Asset Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 35.8% during the first quarter. Cacti Asset Management LLC now owns 36,000 shares of the company valued at $1,212,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 283.2% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 36,892 shares of the company valued at $1,198,000 after purchasing an additional 27,264 shares in the last quarter. Institutional investors hold 5.59% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Fresenius Medical Care AG & Co. KGaA didn’t make the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.